Adalimumab biosimilar (Mylan/Biocon)

阿达木单抗生物类似药（迈兰制药/拜康公司）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAdalimumab biosimilar (Mylan/Biocon)
Drug Alias Name阿达木单抗生物仿制药（迈兰制药/拜康公司）Adalimumabum (Mylan/Biocon)Adalimumab (Mylan/Biocon)BMO-2MYL-1401-A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease +[9] 
Global Approved IndicationsPlaque psoriasisCrohn DiseaseColitis, Ulcerative +[7] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/07/06
Country/TerritoryBelgiumBulgariaUnited States +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiocon Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMylan Pharmaceuticals IncMylan NvBiocon Ltd
Inactive CompaniesMylan IncMylan Gmbh
Active IndicationsPlaque psoriasisPsoriasisCrohn Disease +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A